Variable | Control (n = 150) | AD continuum (n = 374) | P‐value (group effect) | ||
---|---|---|---|---|---|

Preclinical AD (n = 63) | MCI‐AD (n = 111) | AD dementia (n = 200) | |||

Females, % | 59 | 60 | 60 | 62 | 0.940 |

APOE ε4 carriers, % | 21 | 58a | 52a | 62a | <0.0001 |

Age, years | 62.4 (11) | 70.8 (11)a | 74.3 (9)a | 73.8 (10)a | <0.0001 |

CSF biomarkers | |||||

Aβ_{1–42}, pg/ml | 796 (159) | 414 (98)a | 426 (107)a | 408 (113)a | <0.0001 |

T‐tau, pg/ml | 218 (81) | 450 (428)b | 737 (410)a^{,}c | 920 (564)a^{,}d^{,}e | <0.0001 |

P‐tau_{181P}, pg/ml | 43 (12) | 66 (39)a | 95 (32)a^{,}d | 102 (44)a^{,}d | <0.0001 |

Aβ, amyloid β‐peptide; AD, Alzheimer's disease; APOE, apolipoprotein E; CSF, cerebrospinal fluid; MCI‐AD, MCI due to AD; P‐tau

_{181P}, tau phosphorylated at threonine 181; T‐tau, total tau.Data are expressed as percent (%) or mean (SD), as appropriate. Probability values (

*P*) denote differences between groups.*APOE*genotype was available in 103 controls (69%), 39 preclinical AD (62%), 89 MCI‐AD (80%), and 148 AD dementia (74%). Only Aβ_{1–42}values measured by the INNOTEST ELISA are included; Aβ_{1–42}values from Bonn group (measured with MSD platform) are excluded.Chi‐square statistics were used for the group comparisons of gender and

*APOE*ε4 carrier. One‐way ANOVA was used to compare age and CSF biomarkers between groups. The*P*‐values indicated in the last column refer to the group effects in these tests. Significant group effects were followed by Bonferroni‐corrected pair‐wise*post hoc*tests.↵a

*P*< 0.0001 versus controls.↵b

*P*= 0.002 versus controls.↵c

*P*= 0.0001 versus preclinical AD.↵d

*P*< 0.0001 versus preclinical AD.↵e

*P*= 0.002 versus MCI‐AD.